---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-041344"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2024-09-18T23:59:59+00:00"
generated_at: "2026-05-31T03:58:56.812020+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Roivant's Dermavant to be acquired by Organon for $1.2B

## Summary
- Organon (OGN) will acquire Dermavant, a Roivant (ROIV) subsidiary, for $1.2B in cash and milestone payments.
- Deal includes VTAMA cream (tapinarof) 1%, approved for plaque psoriasis in adults (May 2022).
- sNDA for atopic dermatitis under FDA review; PDUFA decision expected Q4 2024.
- VTAMA is a once-daily steroid-free topical with no safety label warnings or duration/BSA restrictions.

## SEC filing metadata
- accession: 0001140361-24-041344
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2024-09-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036124041344/0001140361-24-041344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036124041344/ef20036017_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-041344
- JSON: https://secwatch.observer/filing/0001140361-24-041344.json
- Plain text: https://secwatch.observer/filing/0001140361-24-041344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.